Emphysema Market Report 2026

The emphysema market size has grown steadily in recent years. It will grow from $4.94 billion in 2025 to $5.17 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to smoking prevalence, air pollution exposure, aging population, respiratory disease awareness, healthcare access expansion.

The emphysema market size is expected to see steady growth in the next few years. It will grow to $6.19 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to early screening initiatives, home-based respiratory care, advanced diagnostic adoption, chronic disease management focus, environmental health regulations. Major trends in the forecast period include rising prevalence of chronic respiratory diseases, increased focus on early diagnosis of copd, growth in long-term oxygen therapy, expansion of pulmonary rehabilitation programs, emphasis on smoking cessation interventions.

The growing prevalence of respiratory infections is expected to drive the growth of the emphysema market in the coming years. Respiratory infections are illnesses that affect the respiratory system, including the sinuses, throat, airways, and lungs. The increase in respiratory infections is attributed to factors such as pollution, climate change, antimicrobial resistance, urbanization, and the emergence of new and evolving pathogens. These infections accelerate the progression of emphysema by triggering inflammation, causing tissue damage, and increasing airway obstruction, which further impairs lung function. For example, in November 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the United States reported 9,633 tuberculosis (TB) cases in 2023, representing a 15.6% increase from 8,332 cases in 2022, with the incidence rate rising from 2.5 to 2.9 per 100,000 people. Therefore, the increasing prevalence of respiratory infections is driving the growth of the emphysema market.

Major companies operating in the emphysema market are concentrating on medical innovations, such as inhaled dual inhibitors of phosphodiesterase 3 and phosphodiesterase 4, to deliver advanced therapies that improve lung function, reduce inflammation, and enhance overall disease management, thereby supporting better respiratory health and quality of life. An inhaled dual phosphodiesterase 3 and phosphodiesterase 4 inhibitor is a medication designed to block both enzymes in the lungs, helping to relax the airways and decrease inflammation, which improves breathing in conditions such as chronic obstructive pulmonary disease. For instance, in June 2024, Verona Pharma plc, a UK-based pharmaceutical company, launched Ohtuvayre (ensifentrine), the first inhaled dual PDE3 and PDE4 inhibitor approved by the US Food and Drug Administration for the maintenance treatment of chronic obstructive pulmonary diseases, including emphysema, marking the first novel inhaled therapy in more than 20 years. The drug combines bronchodilator and anti-inflammatory effects and is available through specialty pharmacies.

In October 2023, Aileron Therapeutics Inc., a US-based biopharmaceutical company, acquired Lung Therapeutics for an undisclosed amount. Through this acquisition, Aileron Therapeutics aims to expand its development pipeline by gaining access to multiple clinical-stage therapies, including LTI-03, a novel Caveolin-1-related peptide intended for the treatment of idiopathic pulmonary fibrosis, to address severe lung conditions with limited or no approved treatment options. Lung Therapeutics is a US-based pharmaceutical company focused on developing therapies for lung diseases and injuries, including emphysema.

Major companies operating in the emphysema market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., ResMed Inc., Chiesi Farmaceutici S.p.A., VIDA Diagnostics Inc., Pulmonx Corporation, F Hoffmann‑La Roche Ltd, Cipla Limited, Abbott Laboratories, Astellas Pharma Inc., Covis Pharma Group, FindAir Sp z o o, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Zydus Lifesciences, Theravance Biopharma Inc, Pulmatrix Inc, Genentech, Dimerix Ltd, InMed Pharmaceuticals Inc.

North America was the largest region in the emphysema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the emphysema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the emphysema market by increasing costs of imported respiratory devices, diagnostic equipment, and therapeutic supplies. Hospitals and clinics in developed regions are most affected due to reliance on imported respiratory care products. These tariffs increase treatment costs by raising expenses for diagnostic imaging, oxygen therapy, and pulmonary support devices, impacting chronic disease management. However, they support domestic production of respiratory equipment, strengthening local manufacturing capacity and supply stability.

The emphysema market research report is one of a series of new reports that provides emphysema market statistics, including emphysema industry global market size, regional shares, competitors with a emphysema market share, detailed emphysema market segments, market trends and opportunities, and any further data you may need to thrive in the emphysema industry. This emphysema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Emphysema is a chronic lung condition that damages the air sacs (alveoli) in the lungs, causing breathing difficulties. It is a type of chronic obstructive pulmonary disease (COPD) and is mainly caused by smoking or prolonged exposure to air pollutants. As the alveoli weaken and lose elasticity, air becomes trapped, making it harder for the lungs to expel carbon dioxide and take in oxygen. This leads to shortness of breath, persistent cough, and gradual decline in lung function.

The main types of emphysema are centrilobular and panlobular. Centrilobular refers to the central part of a lung or liver lobule, often linked to conditions such as centrilobular emphysema in the lungs or centrilobular necrosis in the liver. Treatment for emphysema includes medications, therapies, surgical interventions, and other approaches. Diagnosis usually involves imaging tests, lung function assessments, and other diagnostic methods. Common complications include chest infections, collapsed lung, heart issues, lung perforations, and related conditions. Treatment is typically provided in hospitals, clinics, surgical centers, and other healthcare facilities.

The emphysema market consists of revenues earned by entities by providing services such as diagnosis and screening services, oxygen therapy, pulmonary rehabilitation programs, and home healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The emphysema market also includes sales of bronchodilators, corticosteroids, oxygen therapy devices, nebulizers, and pulmonary rehabilitation products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.